Co-Diagnostics, Inc.
$1.67
▼
-4.94%
2026-04-21 06:09:01
co-dx.com
NCM: CODX
Explore Co-Diagnostics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$6.02 M
Current Price
$1.67
52W High / Low
$46.5 / $1.35
Stock P/E
—
Book Value
$9.85
Dividend Yield
—
ROCE
-147.54%
ROE
-1.26%
Face Value
—
EPS
$-35.25
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Devices
Employees
115
Beta
1.43
Debt / Equity
5.99
Current Ratio
3.87
Quick Ratio
3.59
Forward P/E
-0.11
Price / Sales
7.93
Enterprise Value
$-5.71 M
EV / EBITDA
0.19
EV / Revenue
-9.18
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Outset Medical, Inc. | $4.61 | — | $84.32 M | — | -29.4% | -1.06% | $21.98 / $3 | $6.99 |
| 2. | enVVeno Medical Corporation | $12.08 | — | $7.92 M | — | -76.16% | -56.21% | $196.7 / $8.67 | $41.36 |
| 3. | Bioventus Inc. | $10.28 | 38.48 | $874.79 M | — | 10.76% | 13.17% | $10.76 / $5.81 | $2.74 |
| 4. | STERIS plc | $223.73 | 31.17 | $21.95 B | 1.11% | 10.53% | 10.47% | $269.44 / $209.98 | $72.93 |
| 5. | Lumexa Imaging Holdings, Inc. | $9.65 | — | $928.42 M | — | 1.69% | -12.6% | $19.45 / $7.23 | $6.1 |
| 6. | TriSalus Life Sciences, Inc. | $4.6 | — | $285.58 M | — | -113.07% | 131.29% | $7.95 / $3.42 | $-0.68 |
| 7. | TransMedics Group, Inc. | $113.13 | 20.39 | $3.88 B | — | 11.09% | 54.24% | $156 / $84.53 | $13.81 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.26 M | 0.15 M | 0.16 M | 0.05 M | 0.15 M | — |
| Operating Profit | -7.66 M | -7.01 M | -8.06 M | -8.55 M | -11.91 M | — |
| Net Profit | -25.75 M | -5.89 M | -7.73 M | -7.53 M | -11.03 M | — |
| EPS in Rs | -7.15 | -1.63 | -2.15 | -2.09 | -3.06 | -9.6 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.62 M | 3.92 M | 6.81 M | 34.22 M |
| Operating Profit | -31.28 M | -40.08 M | -42.71 M | -11.59 M |
| Net Profit | -46.9 M | -37.64 M | -35.33 M | -14.24 M |
| EPS in Rs | -13.02 | -10.45 | -9.81 | -3.95 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 24.74 M | 63.56 M | 95.32 M | 123.09 M |
| Total Liabilities | 4.11 M | 9.69 M | 9.31 M | 8.57 M |
| Equity | 20.63 M | 53.88 M | 86.01 M | 114.52 M |
| Current Assets | 13.69 M | 32.29 M | 62.14 M | 92.73 M |
| Current Liabilities | 3.54 M | 7.32 M | 5.75 M | 3.87 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -29.14 M | -29.16 M | -22.08 M | 6.57 M |
| Investing CF | 26.27 M | 17.07 M | 15.39 M | -58.17 M |
| Financing CF | 11.81 M | 0.1 M | -1.36 M | -14.03 M |
| Free CF | -29.84 M | -29.9 M | -23.45 M | 5.14 M |
| Capex | -0.7 M | -0.75 M | -1.37 M | -1.43 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | -84.1% | -42.53% | -80.09% | — |
| Earnings Growth % | -24.59% | -6.53% | -148.15% | — |
| Profit Margin % | -7533.62% | -961.37% | -518.68% | -41.61% |
| Operating Margin % | -5025.53% | -1023.75% | -626.92% | -33.87% |
| Gross Margin % | 64.28% | 74.48% | 38.57% | 83.98% |
| EBITDA Margin % | -4847.72% | -988.57% | -608.86% | -30.13% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2026-01-02 | 1:0.0333333 |